Careful planning and preparations for the successful introduction and scale-up of new drugs and regimens (ND&R) is essential. The National Tuberculosis programs and partners should ensure rational use of the ND&R, adequate diagnostic capacity for appropriate treatment allocation, clinical management, monitoring of safety and effectiveness, treatment adherence, provision of patient support when implementing a new TB treatment including BPaL containing regimens for highly resistant tuberculosis.
This is a very hands-on workshop conducted in English without translation during which participants will
• be handed a checklist for BPaL introduction and scale-up planning, which they will use throughout the workshop.
• have an action plan to lead them through the BPaL introduction and programmatic scale-up in their own country in line with international guidance and based on the experience of early implementing countries.
• be able to make programmatic and policy decisions based on the BPaL Operational Research (OR) and surveillance data in their country settings.
Session sponsor: Thomas Lynch, TB Alliance
Chairs: Askar Yedilbayev, WHO; Fraser Wares, KNCV Tuberculosis Foundation
Coordinators: Veriko Mirtskhulava (KNCV Tuberculosis Foundation), Mansa Mbenga (KNCV Tuberculosis Foundation)
Audience: Tuberculosis Program Managers, Clinicians, Epidemiologists, Laboratory professionals, TB/DR-TB International Consultants
- Victor Babawale (National Tuberculosis and Leprosy Control Programme in Nigeria): Preliminary Data on the BPaL Regimen Safety from Nigeria
- Mansa Mbenga (KNCV Tuberculosis Foundation): BPaL Introduction and Scale-up Protocol development
- Veriko Mirtskhulava (KNCV Tuberculosis Foundation): BPaL Implementation Program Monitoring and Evaluation
- Jong Seok Lee (International Tuberculosis Research Center (ITRC): Laboratory Readiness Assessment Toolkit
- Suzanne Staples (THINK): BPaL Implementation Guide